Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Watch Our Video Summary Capturing Obesity News from the Last Two Weeks Top Stories Covered in This Video Ascletis completes US Phase IIa enrollment for once-monthly ASC30 [1] [US 19 Oct 2025] Context: 12-week, randomized, double-blind, placebo-controlled, multi-center Phase IIa in obesity or overweight with comorbidity, three dose cohorts, n=65
Wine RN, McPherson CA, Harry GJ (2009) IGF-1 and pAKT signaling promote hippocampal CA1 neuronal survival following injury to dentate granule cells
Most guidelines recommend avoiding tirzepatide during breastfeeding or using it only if the potential benefit outweighs the potential risk to the infant
received board speaker fees and travel expenses from AstraZeneca, NovoNordisk, Boehringer Ingelheim, Eli Lilly, Bayer and Menarini
: , ,
![Tirzepatide vs. Semaglutide: Which GLP-1 Better Preserves Muscle? [SURMOUNT-5 Data]](https://www.clinicalnutritioncenter.com/wp-content/uploads/2026/04/research-image-2026-04-10-1024x559.jpg)
